Even though ezetimibe lowered cholesterol and changed a key liver enzyme in diabetic and thyroid-deficient rats, it didn’t change the liver’s cholesterol-cleaning receptors at all.

9

Pro

0

Against

Evidence from Studies

Supporting (1)

9

Community contributions welcome

9

Selective Compensatory Induction of Hepatic HMG-CoA Reductase in Response to Inhibition of Cholesterol Absorption

Cohort Study

Animal

2006 May

The study gave diabetic and thyroid-free rats a drug called ezetimibe, which lowered their blood cholesterol but didn’t change the liver’s LDL receptor proteins — just like the claim said.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Selective Compensatory Induction of Hepatic HMG-CoA Reductase in Response to Inhibition of Cholesterol Absorption

Score: 9

DOI: 10.1177/153537020623100510

Similar Assertions

When diabetic rats ate a high-cholesterol diet and were given a drug called ezetimibe, their blood cholesterol dropped dramatically, and their liver made more of a key cholesterol-making enzyme—not by making more of its instructions, but by using the existing instructions more efficiently.

9

0

77%

In rats without thyroid glands that ate a high-cholesterol diet, a drug called ezetimibe lowered their blood cholesterol and brought back their liver’s cholesterol-making enzyme to normal levels, but didn’t change the receptor that clears cholesterol from the blood.

9

0

75%